Company intelligence / Profile preview

Epigen Biosciences, Inc.

San Diego, California, USAepigenbiosciences.com ↗
Ownership
Private
Employees
~9
Development stage
Phase 1
01

Overview

Epigen Biosciences is advancing a pipeline of small molecule therapeutics targeting unmet needs in chronic kidney disease, NASH/MASH, idiopathic pulmonary fibrosis, neurodegenerative diseases such as Alzheimer’s, fragile X syndrome, and brain injuries. All disclosed programs are currently in preclinical development[2][4].

Therapeutic areas
NeurologyGastroenterologyPulmonologyNephrology
Modalities
Small molecules
Industry
Biotech
02

Drug pipeline

3 assets

p70 S6 kinase inhibitor

Preclinical

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Epigen Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epigen Biosciences, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call